Could therapeutic vaccination of cytomegalovirus-seropositive persons prevent reinfection and congenital virus transmission?

Journal of Infectious Diseases

Volumn 203, Issue 11, 2011, Pages 1513-1516

  Schleiss, Mark R ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS VACCINE; GLYCOPROTEIN B; MIFAMURTIDE; PLACEBO;

ANTIBODY TITER; CONGENITAL INFECTION; COST BENEFIT ANALYSIS; CYTOMEGALOVIRUS INFECTION; HUMAN; IMMUNE RESPONSE; INFECTION PREVENTION; NEUROLOGICAL COMPLICATION; NONHUMAN; NOTE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REINFECTION; SEROCONVERSION; TREATMENT RESPONSE; VERTICAL TRANSMISSION; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; CLINICAL TRIALS AS TOPIC; CYTOMEGALOVIRUS INFECTIONS; CYTOMEGALOVIRUS VACCINES; FEMALE; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; VACCINATION;

EID: 79956210577     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir144     Document Type: Note

References (38)

1. Kenneson A, Cannon MJ. Review and metaanalysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol 2007; 17:253-76. (Pubitemid 47066638)
2. Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol 2007; 17:355-63. (Pubitemid 47425872)
3. Bale JF, Miner L, Petheram SJ. Congenital cytomegalovirus infection. Curr Treat Options Neurol 2002; 4:225-30.
4. Cheeran MC, Lokensgard JR, Schleiss MR. Neuropathogenesis of congenital cytomegalovirus infection: disease mechanisms and prospects for intervention. Clin Microbiol Rev 2009; 22:99-126.
5. Williamson WD, Demmler GJ, Percy AK, Catlin FI. Progressive hearing loss in infants with asymptomatic congenital cytomegalovirus infection. Pediatrics 1992; 90:862-6.
6. Fowler KB, McCollister FP, Dahle AJ, et al. Progressive and fluctuating sensorineural hearing loss in children with asymptomatic congenital cytomegalovirus infection. J Pediatr 1997; 130:624-30. (Pubitemid 27492655)
7. Foulon I, Naessens A, Foulon W, et al. A 10-year prospective study of sensorineural hearing loss in children with congenital cytomegalovirus infection. J Pediatr 2008; 153:84-8.
8. Cannon MJ, Davis KF. Washing our hands of the congenital cytomegalovirus disease epidemic. BMC Public Health 2005; 5:70.
9. Jeon J, Victor M, Adler SP, et al. Knowledge and awareness of congenital cytomegalovirus among women. Infect Dis Obstet Gynecol 2006; 2006:80383.
10. Demmler-Harrison GJ. Congenital cytomegalovirus: public health action towards awareness, prevention, and treatment. J Clin Virol 2009; 46:S1-S5.
11. Arvin AM, Fast P, Myers M, et al. Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clin Infect Dis 2004; 39:233-9. (Pubitemid 38971495)
12. Stratton KR, Durch JS, Lawrence RS. (eds). Vaccines for the 21st century: A tool for decisionmaking, Committee to Study Priorities for Vaccine Development, Division of Health Promotion and Disease Prevention. Washington, DC: Natl Acad Press, 1999.
13. Sung H, Schleiss MR. Update on the current status of cytomegalovirus vaccines. Expert Rev Vaccines 2010; 9:1303-14.
14. Spaete RR. A recombinant subunit vaccine approach to HCMV vaccine development. Transplant Proc 1991; 23(Suppl 3):90-6.
15. Pass RF, Duliege AM, Boppana S, et al. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J Infect Dis 1999; 180:970-5. (Pubitemid 30070176)
16. Frey SE, Harrison C, Pass RF, et al. Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine. J Infect Dis 1999; 180:1700-3. (Pubitemid 29506478)
17. Mitchell DK, Holmes SJ, Burke RL, et al. Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers. Pediatr Infect Dis J 2002; 21:133-8. (Pubitemid 34150611)
18. Fowler KB, Stagno S, Pass RF. Maternal immunity and prevention of congenital cytomegalovirus infection. JAMA 2003; 289:1008-11. (Pubitemid 37432932)
19. Pass RF, Zhang C, Evans A, et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 2009; 360:1191-9.
20. Zhang C, Buchanan H, Andrews W, et al. Detection of cytomegalovirus infection during a vaccine clinical trial in healthy young women: seroconversion and viral shedding. J Clin Virol 2006; 35:338-42. (Pubitemid 43188985)
21. Ahlfors K, Ivarsson SA, Harris S. Report on a long-term study of maternal and congenital cytomegalovirus infection in Sweden. Review of prospective studies available in the literature. Scand J Infect Dis 1999; 31:443-57. (Pubitemid 29516202)
22. Boppana SB, Rivera LB, Fowler KB, et al. Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N Engl J Med 2001; 344:1366-71. (Pubitemid 32378391)
23. Gaytant MA, Rours GI, Steegers EA, et al. Congenital cytomegalovirus infection after recurrent infection: case reports and review of the literature. Eur J Pediatr 2003; 162:248-53. (Pubitemid 36442677)
24. Novak Z, Ross SA, Patro RK, et al. Cytomegalovirus strain diversity in seropositive women. J Clin Microbiol 2008; 46:882-6. (Pubitemid 351379973)
25. Yamamoto AY, Mussi-Pinhata MM, Boppana SB, et al. Human cytomegalovirus reinfection is associated with intrauterine transmission in a highly cytomegalovirusimmune maternal population. Am J Obstet Gynecol 2010; 202:297 e1-e8.
26. Ross SA, Arora N, Novak Z, et al. Cytomegalovirus reinfections in healthy seroimmune women. J Infect Dis 2010; 201:386-9.
27. Hansen SG, Powers CJ, Richards R, et al. Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus. Science 2010; 328:102-6.
28. Sabbaj S, Pass RF, Pichon S, Goepfert PA. CMV Glycoprotein B vaccine is capable of boosting both antibody and CD4 T cell responses to CMV in chronically infected women. J Infect Dis. 2011; 203. doi: 10.1093/infdis/jir138.
29. Wang C, Zhang X, Bialek S, Cannon MJ. Attribution of congenital cytomegalovirus infection to primary versus non-primary maternal infection. Clin Infect Dis 2011; 52:e11-e13.
30. Arora N, Novak Z, Fowler KB, Boppana SB, Ross SA. Cytomegalovirus viruria and DNAemia in healthy seropositive women. J Infect Dis 2010; 202:1800-3.
31. Murthy S, Hayward GS, Wheelan S, et al. Detection of a single identical cytomegalovirus (CMV) strain in recently seroconverted young women. PLoS One 2011; 6:e15949.
32. Pignatelli S, Lazzarotto T, Gatto MR, et al. Cytomegalovirus gN genotypes distribution among congenitally infected newborns and their relationship with symptoms at birth and sequelae. Clin Infect Dis 2010; 51:33-41.
33. Arav-Boger R, Battaglia CA, Lazzarotto T, et al. Cytomegalovirus (CMV)-encoded UL144 (truncated tumor necrosis factor receptor) and outcome of congenital CMV infection. J Infect Dis 2006; 194:464-73. (Pubitemid 44162657)
34. Heineman TC, Schleiss M, Bernstein DI, et al. A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines. J Infect Dis 2006; 193:1350-60. (Pubitemid 43673381)
35. Slavuljica I, Busche A, Babić M, et al. Recombinant mouse cytomegalovirus expressing a ligand for the NKG2D receptor is attenuated and has improved vaccine properties. J Clin Invest 2010; 120:4532-45.
36. Schleiss MR. Can we build it better? Using BAC genetics to engineer more effective cytomegalovirus vaccines. J Clin Invest 2010; 120:4192-7.
37. Autran B, Carcelain G, Combadiere B, Debre P. Therapeutic vaccines for chronic infections. Science 2004; 305: 205-8. (Pubitemid 38886726)
38. Berzofsky JA, Ahlers JD, Janik J, et al. Progress on new vaccine strategies against chronic viral infections. J Clin Invest 2004; 114:450-62. (Pubitemid 39572092)